|
|
Volumn 19, Issue 8, 2013, Pages 953-953
|
|
Trials challenging hiv drug doses could usher in huge cost cuts
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
BENZOXAZINE DERIVATIVE;
EFAVIRENZ;
BLOOD;
CLINICAL TRIAL (TOPIC);
COST;
DOSE RESPONSE;
DRUG EFFECT;
ECONOMICS;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
NOTE;
VIROLOGY;
ANTI-HIV AGENTS;
BENZOXAZINES;
CLINICAL TRIALS AS TOPIC;
COSTS AND COST ANALYSIS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
HIV;
HIV INFECTIONS;
HUMANS;
|
|
EID: 84886745831
PISSN: 10788956
EISSN: 1546170X
Source Type: Journal
DOI: 10.1038/nm0813-953 Document Type: Article |
|
Times cited : (1)
|
|
References (0)
|